Released Feb 17, 2022, after the close
10-K filed Mar 8, 2022, 67 days after period end · 0001162194-22-000021
Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$38.27M$38.27M derived−14.2% vs Q4 2020+34.2% vs Q3 2021
Net Income-$9.43M-$9.43M derivedN/M vs Q4 2020N/M vs Q3 2021
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$11,259,000N/M
Operating Cash Flowderived-$7,002,000N/M
Free Cash Flowderived-$7,465,000N/M
Margins · derived
Operating margin-29.4%+8.5 pt vs Q4 2020
Net margin-24.6%+15.8 pt vs Q4 2020
What the release said
The release
Same quarter
| Metric | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019 | Q4 2018 |
|---|---|---|---|---|
| Revenue | $38.27M | $44.61M | $32.44M | $32.33M |
| Net Income | -$9.43M | -$18.03M | -$12.69M | -$14.78M |
| EPS Diluted | — | -$0.24 | -$0.18 | -$0.36 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR